Showing 141 - 160 results of 10,261 for search '(((( 50 c decrease ) OR ( 50 ((ng decrease) OR (nn decrease)) ))) OR ( e point decrease ))', query time: 0.45s Refine Results
  1. 141
  2. 142
  3. 143
  4. 144
  5. 145

    Insufficient disulfide bond formation results in a decrease in alkaline phosphatase activity and accumulation of the reduced form of DegP in LCFA-utilizing cells. by Kanchan Jaswal (9542107)

    Published 2020
    “…The band corresponding to AP is shown (Mol. wt. ~50 kDa). <i>(C) Compromised DsbA-DsbB machinery is responsible for the decrease in alkaline phosphatase activity in cells utilizing oleate</i>. …”
  6. 146

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  7. 147

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  8. 148
  9. 149
  10. 150
  11. 151
  12. 152
  13. 153
  14. 154
  15. 155
  16. 156
  17. 157
  18. 158
  19. 159
  20. 160